The authors demonstrated in vitro that the addition of the hepatocyte growth factor (MET ligand) to the melanoma cell lines with the KIT mutation was able to increase cell viability despite the presence of dasatinib, which was reversed by the addition of crizotinib [74]. The gene discussed is KIT; the disease is melanoma.